期刊文献+

表皮生长因子受体抑制剂C225对人食管癌细胞EC109的生长抑制及促凋亡作用研究

Study of growth arrest and apoptosis of esophageal carcinoma EC109 cells induced by EGFR inhibitor of C225
原文传递
导出
摘要 目的探讨表皮生长因子受体(epithelial growth factor receptor,EGFR)抑制剂C225对人食管癌EC109细胞的生长抑制及凋亡的影响。方法通过不同浓度的C225作用于人食管癌EC109细胞,MTT法检测EC109细胞抑制率,流式细胞仪检测细胞凋亡率及细胞周期,瑞氏染色和倒置相差显微镜观察EC109细胞形态学变化。计量资料采用t检验,率的比较采用单因素方差分析,P<0.05为差异有统计学意义。结果经C225作用后,EC109细胞凋亡率增加,其生长明显受到抑制,经40μmol/L的C225作用72 h后,染色后和相差显微镜观察到EC109细胞呈现典型细胞凋亡改变,流式细胞仪能检测到在G0/G1期前出现凋亡特有的亚二倍体峰(APO峰)。且C225对食管EC109细胞的抑制率与C225的浓度及作用时间呈正相关(r=0.935、0.956,均P<0.05),凋亡率亦与C225的浓度及作用时间均呈显著正相关(r=0.941、0.962,均P<0.05)。结论 C225可抑制食管癌EC109细胞生长,并诱导其凋亡。 Objective To explore the effects of C225 on growth arrest and apoptosis of human esophageal carcinoma EC109 cells.Methods Different concentrations of C225 were used to manage human esophageal EC109 cells.The inhibition rate was detected by MTr assay.Apoptosis and cell cycle were detected by flow cytometry(FCM).Wright staining and phase contrast micro- scope were used to observe the morphological change.The t test was used for measurement data,compared with single factor ANOVA rote,P〈0.05 was considered statistically significant.Results After management with C225,the radio of cell apoptosis increased, and the growth of cells was inhibited obviously.Typical cell apoptosis was observed after management with 40μmol/L C225 for 72 h,which was detected by Wright staining and phase contrast microscope.Hypodiploid peak(APO peak) before the G0/G1 phase was detected by flow cytometer.Moreover, the effect of growth arrest had a positive correlation with the concentration and acting duration of C225(r=0.935,0.956,P〈0.05),and the rate of apoptosis also showed a positive correlation with the concentration and acting duration of C225(r=0.941,0.962,P〈0.05).Conclusion C225 can inhibit the growth of EC109 cells,and induce apoptosis.
出处 《社区医学杂志》 2014年第15期1-4,共4页 Journal Of Community Medicine
关键词 表皮生长因子受体 C225 食管肿瘤 细胞凋亡 细胞周期 Epithelial growth factor receptor C225 Esophageal neoplasms Apoptosis Cell cycle
  • 相关文献

参考文献16

  • 1Milas L,Mason K,Hunter N,et al.In vivo enhancemeng of tumor radioresponse by C225 antiepidemal growth factor receptor antibody[J].Clin Cancer Res,2000,6:701-708.
  • 2Bruns C J,Harbison MT,Davis DW,et al.Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms[J].Clin Cancer Res,2000,6(5):1936-1948.
  • 3Langer CJ.Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy:focus on NSCLC[J].Int J Radiat Oncol Biol Phys,2004,58:991-1002.
  • 4Ptister D,Aliff T,Kraus D,et al.Concurrent cetuximab,cisplatin,and concomitant boost radiation therapy(RT)for locoregionally advanced,squamous cell head and neck cancer(SCCHN):Preliminary evaluation of a new combined-modality paradigm[J].Proc Am Soe Clin Oncol,2003,22:495.
  • 5Bonner J,Giralt P,Harari R,et al.Cetuximab prolongs survival in patients with loenregionally ad vanced squamous cell carcinoma of head and neck:AphaseⅢstudy of high dose radiation therapy with or without cetuximab[J].Proc Am Soc Clin Oncol,2004,23:489.
  • 6邵令方,高宗人,卫功铨,许金良,陈明耀,程金华.食管癌和贲门癌的外科治疗[J].中华外科杂志,2001,39(1):44-46. 被引量:256
  • 7Huether A,Hpfner M,Baradari V,et al.EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer[J].Biochem Pharmacol,2005,70(11):1568.
  • 8Rivera F,Vega-Villegas ME,Lopez-Brea MI.Cetuximab,its clinical use and future perspectives[J].Anticancer Drugs,2008,19(2):99.
  • 9韦玮,郭荣平,李锦清,徐立,石明,张亚奇.西妥昔单抗联合厄洛替尼对人肝癌细胞的体外抑制作用[J].癌症,2008,27(4):386-392. 被引量:12
  • 10Inoue KJ,slaton JW,Perrotte P,et al.Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma[J].Clin cancer Res,2000,6:4874-4884.

二级参考文献65

共引文献266

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部